체형 개선 필러 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 프리필드 시린지별, 지역별, 부문별 예측(2025-2030년)

Body Augmentation Fillers Market Growth & Trends:

The global body augmentation fillers market size is anticipated to reach USD 3.03 billion by 2030 and is projected to grow at a CAGR of 17.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for non-invasive cosmetic procedures primarily drives market growth. As societal norms evolve, there is a growing acceptance and desire among individuals to enhance their physical appearance by improving the structure of their body parts, such as hands, breasts, and buttocks, without undergoing surgical interventions. This trend is particularly prevalent among younger demographics, who are more inclined to seek out aesthetic enhancements through body augmentation fillers that offer immediate results with minimal downtime.

Advancements in body augmentation filler technology contribute significantly to this growth, as modern fillers provide longer-lasting effects and improved safety profiles, making them more appealing to consumers. Based on the 2023 procedural statistics released by the ASPS, there were a total of 304,181 breast augmentation procedures, encompassing both initial placements and revisions of implants. Furthermore, there was a significant uptick in the number of breast lifts performed, totaling 153,600, representing a 7 percent increase compared to the previous year.

Rising awareness regarding personal aesthetics and self-care contributes to market growth. With the influence of social media and celebrity culture, individuals are increasingly motivated to pursue cosmetic enhancements through hyaluronic acid fillers to achieve desired looks. This heightened focus on physical appearance led to a surge in demand for various body augmentation procedures, including hand rejuvenation, breast augmentation, buttock augmentation, and other body augmentation treatments. In July 2024, a five-year study was concluded, demonstrating the safety and effectiveness of HA dermal fillers for buttock augmentation. Conducted in Italy and the UAE on 91 patients using HYAcorp MLF1 and MLF2, the research highlighted a lower risk of adverse events compared to traditional implant-based methods, confirming the high safety and efficacy of HA fillers for nonsurgical gluteal enhancement over a follow-up period of almost 4 years and 7 months.

Body Augmentation Fillers Market Report Highlights:

• The Hyaluronic acid (HA) segment led the market with the largest revenue share of 79.8% in 2024, and is expected to grow at the fastest CAGR over the forecast period, due to its biocompatibility and ability to provide natural-looking results, as well as increase consumer demand for minimally invasive cosmetic procedures.
• Based on application, the hand rejuvenation segment led the market with the market with the largest revenue share of 44.7% in 2024, due to increasing demand for aesthetic procedures among aging populations seeking to improve the appearance of their hands, along with advancements in filler technologies that offer longer-lasting and more natural-looking results
• Based on application, the buttock augmentation segment is expected to grow at the fastest CAGR over the forecast period owing to increasing consumer demand for aesthetic enhancements and the growing popularity of non-surgical procedures that offer minimal downtime.
• Based on pre-filled syringes, the <5ml segment accounted for the largest revenue share in 2024, due to advancements in filler formulations that offer improved safety profiles and longer-lasting results that contribute significantly to market growth.
• Based on pre-filled syringes, the 10ml segment is expected to grow at the fastest CAGR over the forecast period, owing to increasing demand for minimally invasive cosmetic procedures and the convenience of ready-to-use products that enhance efficiency and reduce waste during application.
• In March 2024, Prollenium Medical Technologies introduced a new addition to their Revanesse line, called Revise+. This dermal filler is aimed at treating sensitive spots such as the tear trough. It's made with high molecular weight hyaluronic acid, featuring a 12mg HA/ml concentration, perfect for periorbital treatments. Revise+ is praised for its soft, malleable gel form, which ensures low swelling and effective tissue integration and viscosity, making it suitable for both superficial and deep periorbital applications.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Application Segment
  • 1.2.3. Pre-filled Syringes Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Body Augmentation Fillers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing demand for aesthetic procedures
    • 3.2.1.2. Advancements in filler technologies
    • 3.2.1.3. Growing awareness of non-surgical cosmetic enhancements
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High costs
    • 3.2.2.2. Regulatory challenges
• 3.3. Body Augmentation Fillers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Body Augmentation Fillers Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Body Augmentation Fillers Market Product Movement Analysis
• 4.3. Global Body Augmentation Fillers Market Size & Trend Analysis, by Product 2018 to 2030 (USD Million)
• 4.4. Hyaluronic Acid (HA)
  • 4.4.1. Hyaluronic acid (HA) market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Calcium Hydroxylapatite (CaHA)
  • 4.5.1. Calcium hydroxylapatite (CaHA) market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Polymethylmethacrylate (PMMA) & Polycaprolactone (PCL)
  • 4.6.1. Polymethylmethacrylate (PMMA) & polycaprolactone (PCL) market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Body Augmentation Fillers Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Body Augmentation Fillers Market Application Movement Analysis
• 5.3. Global Body Augmentation Fillers Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Hand Rejuvenation
  • 5.4.1. Hand rejuvenation market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Breast Augmentation
  • 5.5.1. Breast augmentation market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Buttock Augmentation
  • 5.6.1. Buttock augmentation market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Body Augmentation Fillers Market: Pre-filled Syringes Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Body Augmentation Fillers Market Pre-filled Syringes Movement Analysis
• 6.3. Global Body Augmentation Fillers Market Size & Trend Analysis, by Pre-filled Syringes 2018 to 2030 (USD Million)
• 6.4. <5ml
  • 6.4.1. <5ml market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. 10ml
  • 6.5.1. 10ml market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. 20ml
  • 6.6.1. 20ml market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Body Augmentation Fillers Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Regulatory framework
    • 7.5.8.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Competitive scenario
    • 7.5.9.3. Regulatory framework
    • 7.5.9.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Regulatory framework
    • 7.6.7.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.2. Turkey
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Turkey market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.3. Iran
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Iran market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.4. South Africa
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.5. Saudi Arabia
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Regulatory framework
    • 7.8.5.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.6. UAE
    • 7.8.6.1. Key country dynamics
    • 7.8.6.2. Competitive scenario
    • 7.8.6.3. Regulatory framework
    • 7.8.6.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.7. Kuwait
    • 7.8.7.1. Key country dynamics
    • 7.8.7.2. Competitive scenario
    • 7.8.7.3. Regulatory framework
    • 7.8.7.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. AbbVie
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Galderma
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Merz GmbH and Co. KGaA
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. IBSA Farmaceutici Italia Srl
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Teoxane
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Sinclair
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. BioScience GmbH
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Hugel
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. BioPlus
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Medytox, Inc.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives